Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atumelnant open-label extension study in congenital adrenal hyperplasia
NL-OMON61556Phase 2Not yet recruiting
- Sponsor
- Crinetics Pharmaceuticals
- Start
- Feb 2025
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of atumelnant in congenital adrenal hyperplasia (CAH) (2 arms), sponsored by Crinetics Pharmaceuticals. Primary endpoints: Incidence of treatment-emergent adverse events, Incidence of glucocorticoid deficiency or adrenal insufficiency and adrenal crisis and 2 more. Planned start Feb 2025; status: not yet recruiting.
02
Drugs
atumelnant
03
Conditions
congenital adrenal hyperplasia (CAH)
Beyond the preview
Go deeper on NL-OMON61556.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON61556.